(IMCD) IMCD - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0010801007
Stock: Chemicals, Ingredients, Additives, Lubricants, Energy
Total Rating 38
Risk 81
Buy Signal -1.13
| Risk 5d forecast | |
|---|---|
| Volatility | 40.0% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.43 |
| Alpha | -49.24 |
| Character TTM | |
|---|---|
| Beta | 0.195 |
| Beta Downside | -0.251 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.75% |
| CAGR/Max DD | -0.34 |
Description: IMCD IMCD March 04, 2026
IMCD N.V. is a global distributor of specialty chemicals and ingredients. The company operates across Europe, the Middle East, Africa, North and South America, and Asia-Pacific regions. This business model typically involves acting as an intermediary between chemical producers and industrial customers, offering value-added services like technical support and logistics.
IMCDs product portfolio is extensive, covering various sectors. For instance, it supplies ingredients for personal care products, such as UV sunscreens and emollients. It also provides materials for industrial applications, including adhesives, flame retardants, and various polymers. Additionally, IMCD offers solutions for food and nutrition, home care, and lubricants. These diverse product offerings cater to a wide range of end-user industries.
To gain a deeper understanding of IMCDs market performance and peer comparisons, consider exploring its detailed financials on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 495.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.55 > 1.0 |
| NWC/Revenue: 7.98% < 20% (prev 23.03%; Δ -15.05% < -1%) |
| CFO/TA 0.13 > 3% & CFO 601.5m > Net Income 495.8m |
| Net Debt (1.46b) to EBITDA (1.10b): 1.33 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (59.1m) vs prev 3.35% < -2% |
| Gross Margin: 18.07% > 18% (prev 0.12%; Δ 1796 % > 0.5%) |
| Asset Turnover: 200.3% > 50% (prev 91.07%; Δ 109.2% > 0%) |
| Interest Coverage Ratio: 7.13 > 6 (EBITDA TTM 1.10b / Interest Expense TTM 115.3m) |
Altman Z'' 3.22
| A: 0.16 (Total Current Assets 1.80b - Total Current Liabilities 1.03b) / Total Assets 4.64b |
| B: 0.22 (Retained Earnings 1.00b / Total Assets 4.64b) |
| C: 0.17 (EBIT TTM 822.4m / Avg Total Assets 4.76b) |
| D: 0.26 (Book Value of Equity 678.4m / Total Liabilities 2.59b) |
| Altman-Z'' Score: 3.22 = A |
Beneish M -2.90
| DSRI: 0.53 (Receivables 853.7m/754.5m, Revenue 9.53b/4.44b) |
| GMI: 0.64 (GM 18.07% / 11.65%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.55) |
| SGI: 2.14 (Revenue 9.53b / 4.44b) |
| TATA: -0.02 (NI 495.8m - CFO 601.5m) / TA 4.64b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of IMCD shares?
As of March 07, 2026, the stock is trading at EUR 73.16 with a total of 522,559 shares traded.
Over the past week, the price has changed by -7.70%, over one month by -17.54%, over three months by -4.49% and over the past year by -45.74%.
Over the past week, the price has changed by -7.70%, over one month by -17.54%, over three months by -4.49% and over the past year by -45.74%.
Is IMCD a buy, sell or hold?
IMCD has no consensus analysts rating.
What are the forecasts/targets for the IMCD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 108.4 | 48.2% |
| Analysts Target Price | - | - |
IMCD Fundamental Data Overview March 01, 2026
Market Cap USD = 5.59b (4.81b EUR * 1.1632 EUR.USD)
P/E Trailing = 17.8118
P/E Forward = 12.7389
P/S = 1.0008
P/B = 2.4324
Revenue TTM = 9.53b EUR
EBIT TTM = 822.4m EUR
EBITDA TTM = 1.10b EUR
Long Term Debt = 1.38b EUR (estimated: total debt 1.70b - short term 325.0m)
Short Term Debt = 325.0m EUR (from shortTermDebt, last quarter)
Debt = 1.70b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.46b EUR (from netDebt column, last quarter)
Enterprise Value = 6.27b EUR (4.81b + Debt 1.70b - CCE 238.6m)
Interest Coverage Ratio = 7.13 (Ebit TTM 822.4m / Interest Expense TTM 115.3m)
EV/FCF = 10.92x (Enterprise Value 6.27b / FCF TTM 574.4m)
FCF Yield = 9.16% (FCF TTM 574.4m / Enterprise Value 6.27b)
FCF Margin = 6.03% (FCF TTM 574.4m / Revenue TTM 9.53b)
Net Margin = 5.20% (Net Income TTM 495.8m / Revenue TTM 9.53b)
Gross Margin = 18.07% ((Revenue TTM 9.53b - Cost of Revenue TTM 7.81b) / Revenue TTM)
Gross Margin QoQ = 8.77% (prev 26.02%)
Tobins Q-Ratio = 1.35 (Enterprise Value 6.27b / Total Assets 4.64b)
Interest Expense / Debt = 2.71% (Interest Expense 46.1m / Debt 1.70b)
Taxrate = 24.91% (29.1m / 117.0m)
NOPAT = 617.5m (EBIT 822.4m * (1 - 24.91%))
Current Ratio = 1.73 (Total Current Assets 1.80b / Total Current Liabilities 1.03b)
Debt / Equity = 0.83 (Debt 1.70b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = 1.33 (Net Debt 1.46b / EBITDA 1.10b)
Debt / FCF = 2.55 (Net Debt 1.46b / FCF TTM 574.4m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 495.8m / Total Assets 4.64b)
RoE = 24.85% (Net Income TTM 495.8m / Total Stockholder Equity 1.99b)
RoCE = 24.38% (EBIT 822.4m / Capital Employed (Equity 1.99b + L.T.Debt 1.38b))
RoIC = 24.62% (NOPAT 617.5m / Invested Capital 2.51b)
WACC = 7.05% (E(4.81b)/V(6.51b) * Re(8.82%) + D(1.70b)/V(6.51b) * Rd(2.71%) * (1-Tc(0.25)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.76%
[DCF] Terminal Value 84.43% ; FCFF base≈497.6m ; Y1≈613.9m ; Y5≈1.05b
[DCF] Fair Price = 345.7 (EV 21.87b - Net Debt 1.46b = Equity 20.41b / Shares 59.0m; r=7.05% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.79 | EPS CAGR: 96.11% | SUE: 0.11 | # QB: 0
Revenue Correlation: 78.81 | Revenue CAGR: 15.28% | SUE: -0.07 | # QB: 0
EPS current Year (2026-12-31): EPS=5.62 | Chg7d=+0.004 | Chg30d=-0.186 | Revisions Net=-7 | Growth EPS=+8.2% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=6.09 | Chg7d=-0.081 | Chg30d=-0.185 | Revisions Net=-7 | Growth EPS=+8.5% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 7 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 8.8% - Earnings Yield 5.6%)
[Growth] Growth Spread = +2.4% (Analyst 5.6% - Implied 3.2%)
P/E Trailing = 17.8118
P/E Forward = 12.7389
P/S = 1.0008
P/B = 2.4324
Revenue TTM = 9.53b EUR
EBIT TTM = 822.4m EUR
EBITDA TTM = 1.10b EUR
Long Term Debt = 1.38b EUR (estimated: total debt 1.70b - short term 325.0m)
Short Term Debt = 325.0m EUR (from shortTermDebt, last quarter)
Debt = 1.70b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.46b EUR (from netDebt column, last quarter)
Enterprise Value = 6.27b EUR (4.81b + Debt 1.70b - CCE 238.6m)
Interest Coverage Ratio = 7.13 (Ebit TTM 822.4m / Interest Expense TTM 115.3m)
EV/FCF = 10.92x (Enterprise Value 6.27b / FCF TTM 574.4m)
FCF Yield = 9.16% (FCF TTM 574.4m / Enterprise Value 6.27b)
FCF Margin = 6.03% (FCF TTM 574.4m / Revenue TTM 9.53b)
Net Margin = 5.20% (Net Income TTM 495.8m / Revenue TTM 9.53b)
Gross Margin = 18.07% ((Revenue TTM 9.53b - Cost of Revenue TTM 7.81b) / Revenue TTM)
Gross Margin QoQ = 8.77% (prev 26.02%)
Tobins Q-Ratio = 1.35 (Enterprise Value 6.27b / Total Assets 4.64b)
Interest Expense / Debt = 2.71% (Interest Expense 46.1m / Debt 1.70b)
Taxrate = 24.91% (29.1m / 117.0m)
NOPAT = 617.5m (EBIT 822.4m * (1 - 24.91%))
Current Ratio = 1.73 (Total Current Assets 1.80b / Total Current Liabilities 1.03b)
Debt / Equity = 0.83 (Debt 1.70b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = 1.33 (Net Debt 1.46b / EBITDA 1.10b)
Debt / FCF = 2.55 (Net Debt 1.46b / FCF TTM 574.4m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 495.8m / Total Assets 4.64b)
RoE = 24.85% (Net Income TTM 495.8m / Total Stockholder Equity 1.99b)
RoCE = 24.38% (EBIT 822.4m / Capital Employed (Equity 1.99b + L.T.Debt 1.38b))
RoIC = 24.62% (NOPAT 617.5m / Invested Capital 2.51b)
WACC = 7.05% (E(4.81b)/V(6.51b) * Re(8.82%) + D(1.70b)/V(6.51b) * Rd(2.71%) * (1-Tc(0.25)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.76%
[DCF] Terminal Value 84.43% ; FCFF base≈497.6m ; Y1≈613.9m ; Y5≈1.05b
[DCF] Fair Price = 345.7 (EV 21.87b - Net Debt 1.46b = Equity 20.41b / Shares 59.0m; r=7.05% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.79 | EPS CAGR: 96.11% | SUE: 0.11 | # QB: 0
Revenue Correlation: 78.81 | Revenue CAGR: 15.28% | SUE: -0.07 | # QB: 0
EPS current Year (2026-12-31): EPS=5.62 | Chg7d=+0.004 | Chg30d=-0.186 | Revisions Net=-7 | Growth EPS=+8.2% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=6.09 | Chg7d=-0.081 | Chg30d=-0.185 | Revisions Net=-7 | Growth EPS=+8.5% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 7 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 8.8% - Earnings Yield 5.6%)
[Growth] Growth Spread = +2.4% (Analyst 5.6% - Implied 3.2%)